HBS RADIO LIVE

Connect with us

Health Broadcasting Service

Pfizer begins study of mRNA flu vaccine

HBS Reporting

Pfizer begins study of mRNA flu vaccine

Pfizer begins study of mRNA flu vaccine

(Reuters) – Pfizer Inc said on Monday it had dosed the first patient in a trial testing a flu vaccine based on messenger RNA, the same technology used in the COVID-19 shots made by the U.S. drugmaker and BioNTech.

The early-stage trial, conducted in the United States, will test the vaccine in healthy adults ages 65- 85.

“The COVID-19 pandemic allowed us to deliver on the immense scientific opportunity of mRNA. Influenza remains an area where we see a need for vaccines,” said Kathrin Jansen, head of vaccine research and development at Pfizer.

The study will test the safety and immune responses of the vaccine, compared to another FDA-approved influenza vaccine.

Continue Reading
You may also like...
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

More in HBS Reporting